Sort
10,766 grants matching “checkpoint inhibitor”
[18F]-AraG -PET imaging to evaluate immunological response to checkpoint inhibitor therapy (CKI) in patients with advanced solid tumors
$423,444Shivaani Kummar · Stanford University · R01 · FY2020 · CA
Signaling Pathways in Neuronal Cells
$423,414Marsha R Rosner · University Of Chicago · R01 · FY2012 · GM
Signaling Pathways in Neuronal Cells
$423,414Marsha R Rosner · University Of Chicago · R01 · FY2011 · GM
Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma
$423,409David Sidransky · Johns Hopkins University · R01 · FY2025 · CA
Defining the features of T cell response to tumor and self-antigens as predictors of response to checkpoint therapy
$423,377Jane Hoyt Buckner · Benaroya Research Inst At Virginia Mason · R01 · FY2021 · CA
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
$423,354Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2022 · CA
Mechanisms of immunotherapy response and resistance in pancreatic ductal adenocarcinoma
$423,354Ingunn Margarete Stromnes · University Of Minnesota · R01 · FY2023 · CA
Novel regulations of DNA damage repair
$423,276Junjie Chen · University Of Tx Md Anderson Can Ctr · R01 · FY2019 · CA
Metabolic interactions between tumor cells and the immunce system in GBM A potential Achilles heel of GBM for novel therapeutics
$423,255Loic Pierre Deleyrolle · University Of Florida · R01 · FY2022 · NS
Isoprenylcysteine Carboxyl Methyltransferase (ICMT) as a Target in NRAS Driven Melanoma - Resubmission - 1
$423,242Mark Reid Philips · New York University School Of Medicine · R01 · FY2020 · CA
Isoprenylcysteine Carboxyl Methyltransferase (ICMT) as a Target in NRAS Driven Melanoma - Resubmission - 1
$423,242Mark Reid Philips · New York University School Of Medicine · R01 · FY2019 · CA
Defining therapeutic strategies for boosting T-cell infiltration into cold tumors with spatial proteomics and machine learning
$423,078Matthew W. Thomson · California Institute Of Technology · R21 · FY2023 · CA
Unraveling Vascular Mediated Immune Exclusion in Melanoma
$422,971Minah Kim · Columbia University Health Sciences · R21 · FY2024 · CA
Targeting Polo-Like Kinase 1 in Prostate Cancer to Enhance Therapeutic Efficacy
$422,964Zhiguo Li · University Of Kentucky · R01 · FY2024 · CA
Diagnosis and Treatment of APOBEC Mutagenesis in Metastatic Breast Cancer
$422,764Sarat Chandarlapaty · Sloan-Kettering Inst Can Research · P50 · FY2022 · CA
Mechanisms of Apoptosis Dysregulation in AML
$422,758John C Reed · University Of Tx Md Anderson Can Ctr · P01 · FY2010 · CA
Targeting Nucleotide Excision Repair Deficiency to Improve Bladder Sparing Treatment for Muscle Invasive Bladder Cancer
$422,255Kent W Mouw · Dana-Farber Cancer Inst · R01 · FY2023 · CA
ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
$422,252David M. Ashley · Duke University · R01 · FY2022 · CA
Project 1: Decoding, Modeling and Targeting Oncohistones and an Oncohistone-like Protein
$422,216Nada Jabado · Rockefeller University · P01 · FY2023 · CA
Targeting leukemic stem cells in acute myeloid leukemia
$422,159Cheng-Kui Qu · Emory University · R01 · FY2025 · CA
Targeting leukemic stem cells in acute myeloid leukemia
$422,157Cheng-Kui Qu · Emory University · R01 · FY2023 · CA
Engineered Ensemble Nanoimmunotherapies for Cancer
$422,156Rohan Fernandes · George Washington University · R37 · FY2020 · CA
Role of exosomal SPHK1 in ovarian cancer progression
$422,127Sunila Pradeep · Medical College Of Wisconsin · R01 · FY2024 · CA
Studies of the DNA replication checkpoint
$422,111Paul R Russell · Scripps Research Institute, The · R01 · FY2010 · GM
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
$422,092Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2022 · CA